Positive and negative functions of B lymphocytes in tumors

Oncotarget

Volumn 7, Issue 34, 2016, Pages 55828-55839

  Shen, Meng ^a,b   Sun, Qian ^a,b   Wang, Jian ^a,b   Pan, Wei ^a,b   Ren, Xiubao ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

B lymphocytes; Regulatory B cells; Tumor; Tumor immunotherapy; Tumor infiltrating B cells

Indexed keywords

B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL FUNCTION; IMMUNE RESPONSE; TUMOR IMMUNOLOGY; ANIMAL; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; BIOSYNTHESIS; HUMAN; IMMUNOLOGY; LYMPHOCYTE FUNCTION; NEOPLASM; PHYSIOLOGY; REGULATORY B LYMPHOCYTE;

CYTOKINE;

ANIMALS; ANTIBODY FORMATION; ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; B-LYMPHOCYTES, REGULATORY; CYTOKINES; HUMANS; LYMPHOCYTE COOPERATION; NEOPLASMS;

EID: 84983474474     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10094     Document Type: Article

References (97)

1. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. Journal of immunology. 2010; 185(9):4977-4982.
2. Xu L, Li G, Wang J, Fan Y, Wan Z, Zhang S, Shaheen S, Li J, Wang L, Yue C, Zhao Y, Wang F, Brzostowski J, et al. Through an ITIM-independent mechanism the FcgammaRIIB blocks B cell activation by disrupting the colocalized microclustering of the B cell receptor and CD19. Journal of immunology. 2014; 192(11):5179-5191.
3. Ruprecht CR and Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. European journal of immunology. 2006; 36(4):810-816.
4. DeKoter RP, Geadah M, Khoosal S, Xu LS, Thillainadesan G, Torchia J, Chin SS and Garrett-Sinha LA. Regulation of follicular B cell differentiation by the related E26 transformation-specific transcription factors PU.1, Spi-B, and Spi-C. Journal of immunology. 2010; 185(12):7374-7384.
5. Kim MS and Kim TS. Aminoacyl tRNA Synthetase-Interacting Multifunctional Protein 1 acts as a novel B cell-activating factor in vitro and in vivo. Journal of immunology. 2015; 194(10):4729-4736.
6. Mackay F and Schneider P. Cracking the BAFF code. Nature reviews immunology. 2009; 9(7):491-502.
7. Kienzle G and von Kempis J. CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes. International immunology. 2000; 12(1):73-82.
8. Disis ML and Stanton SE. Triple-negative breast cancer: immune modulation as the new treatment paradigm. American Society of Clinical Oncology educational book/ASCO American Society of Clinical Oncology Meeting. 2015:e25-30.
9. Carmi Y, Spitzer MH, Linde IL, Burt BM, Prestwood TR, Perlman N, Davidson MG, Kenkel JA, Segal E, Pusapati GV, Bhattacharya N and Engleman EG. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature. 2015; 521(7550):99-104.
10. Hassan SB, Sorensen JF, Olsen BN and Pedersen AE. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacology and immunotoxicology. 2014; 36(2):96-104.
11. Jackaman C, Cornwall S, Graham PT and Nelson DJ. CD40-activated B cells contribute to mesothelioma tumor regression. Immunology and cell biology. 2011; 89(2):255-267.
12. Chen Y, Chen L, Lu Q, Meng Y, Wang C, Wang L, Wang H, Yu X, Zhang Y, Zhao L, Li B and Guo Y. Optimization of anti-CD20 humanized antibody hu8E4 by site-directed mutation based on epitope analysis. Biochemical and biophysical research communications. 2015; 459(4):617-622.
13. Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an openlabel randomised phase 3 trial. The Lancet oncology. 2014; 15(4):424-435.
14. Shuang YR, Ye DQ, Chen JX, Wu YH, Huang H and Fan GH. Observation of the curative effect of Mabthera in combination with the CHOP regimen in treating invasive B-cell lymphoma: A report of 45 cases. Chinese journal of clinical oncology. 2008:215-218.
15. von Muenchow L, Engdahl C, Karjalainen K and Rolink AG. The selection of mature B cells is critically dependent on the expression level of the co-receptor CD19. Immunology letters. 2014; 160(2):113-119.
16. Zugmaier G, Klinger M, Schmidt M and Subklewe M. Clinical overview of anti-CD19 BiTE((R)) and ex vivo data from anti-CD33 BiTE((R)) as examples for retargeting T cells in hematologic malignancies. Molecular immunology. 2015; 67(2 Pt A):58-66.
17. Gao ZW, Dong K and Zhang HZ. The roles of CD73 in cancer. BioMed research international. 2014; 2014:460654.
18. Forte G, Sorrentino R, Montinaro A, Luciano A, Adcock IM, Maiolino P, Arra C, Cicala C, Pinto A and Morello S. Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. Journal of immunology. 2012; 189(5):2226-2233.
19. Villaruz LC, Kalyan A, Zarour H and Socinski MA. Immunotherapy in lung cancer. Translational lung cancer research. 2014; 3(1):2-14.
20. Santarpia M and Karachaliou N. Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer biology & medicine. 2015; 12(2):74-78.
21. Teixido C, Karachaliou N, Gonzalez-Cao M, Morales-Espinosa D and Rosell R. Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer biology & medicine. 2015; 12(3):259.
22. Hong L, Han Y and Brain L. The role of epidermal growth factor receptor in prognosis and treatment of gastric cancer. Expert review of gastroenterology & hepatology. 2014; 8(1):111-117.
23. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK and Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert opinion on therapeutic targets. 2012; 16(1):15-31.
24. Lemos LG, Victorino VJ, Herrera AC, Aranome AM, Cecchini AL, Simao AN, Panis C and Cecchini R. Trastuzumab-based chemotherapy modulates systemic redox homeostasis in women with HER2-positive breast cancer. International immunopharmacology. 2015; 27(1):8-14.
25. Schrama D, Reisfeld RA and Becker JC. Antibody targeted drugs as cancer therapeutics. Nature reviews drug discovery. 2006; 5(2):147-159.
26. Parker Harp CR, Archambault AS, Sim J, Ferris ST, Mikesell RJ, Koni PA, Shimoda M, Linington C, Russell JH and Wu GF. B cell antigen presentation is sufficient to drive neuroinflammation in an animal model of multiple sclerosis. Journal of immunology. 2015; 194(11):5077-5084.
27. Crawford A, Macleod M, Schumacher T, Corlett L and Gray D. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. Journal of immunology. 2006; 176(6):3498-3506.
28. Szeto GL, Van Egeren D, Worku H, Sharei A, Alejandro B, Park C, Frew K, Brefo M, Mao S, Heimann M, Langer R, Jensen K and Irvine DJ. Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines. Scientific reports. 2015; 5:10276.
29. Zhang L, Bridle BW, Chen L, Pol J, Spaner D, Boudreau JE, Rosen A, Bassett JD, Lichty BD, Bramson JL and Wan Y. Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses. Blood. 2013; 121(13):2432-2439.
30. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH and Nelson BH. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PloS one. 2009; 4(7):e6412.
31. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM and Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clinical cancer research. 2008; 14(16):5220-5227.
32. Nedergaard BS, Ladekarl M, Nyengaard JR and Nielsen K. A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years. Gynecologic oncology. 2008; 108(1):106-111.
33. CandolfiM, Curtin JF, Yagiz K, Assi H, Wibowo MK, Alzadeh GE, Foulad D, Muhammad AK, Salehi S, Keech N, Puntel M, Liu C, Sanderson NR, et al. B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia. 2011; 13(10):947-960.
34. Ghadially H, Ross XL, Kerst C, Dong J, Reske-Kunz AB and Ross R. Differential regulation of CCL22 gene expression in murine dendritic cells and B cells. Journal of immunology. 2005; 174(9):5620-5629.
35. Yoshie O, Imai T and Nomiyama H. Chemokines in immunity. Advances in immunology. 2001; 78:57-110.
36. Ahmed A and Koma MK. Interleukin-33 triggers B1 cell expansion and its release of monocyte/macrophage chemoattractants and growth factors. Scandinavian journal of immunology. 2015; 82(2):118-124.
37. Ladanyi A. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment cell & melanoma research. 2015; 28(5):490-500.
38. Kobayashi T, Hamaguchi Y, Hasegawa M, Fujimoto M, Takehara K and Matsushita T. B cells promote tumor immunity against B16F10 melanoma. The American journal of pathology. 2014; 184(11):3120-3129.
39. Shimabukuro-Vornhagen A, Schlosser HA, Gryschok L, Malcher J, Wennhold K, Garcia-Marquez M, Herbold T, Neuhaus LS, Becker HJ, Fiedler A, Scherwitz P, Koslowsky T, Hake R, et al. Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. Oncotarget. 2014; 5(13):4651-4664. doi: 10.18632/oncotarget.1701
40. Hahne M, Renno T, Schroeter M, Irmler M, French L, Bornard T, MacDonald HR and Tschopp J. Activated B cells express functional Fas ligand. European journal of immunology. 1996; 26(3):721-724.
41. Li Y, Xu DF, Jiang D, Zhao J, Ge JF and Zheng SY. Significance of Fas and FasL protein expression in cardiac carcinoma and local lymph node tissues. International journal of clinical and experimental pathology. 2015; 8(9):11915-11920.
42. Haynes NM, Hawkins ED, Li M, McLaughlin NM, Hammerling GJ, Schwendener R, Winoto A, Wensky A, Yagita H, Takeda K, Kershaw MH, Darcy PK and Smyth MJ. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. Journal of immunology. 2010; 185(1):532-541.
43. Hagn M, Schwesinger E, Ebel V, Sontheimer K, Maier J, Beyer T, Syrovets T, Laumonnier Y, Fabricius D, Simmet T and Jahrsdorfer B. Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21. Journal of immunology. 2009; 183(3):1838-1845.
44. Catalan E, Jaime-Sanchez P, Aguilo N, Simon MM, Froelich CJ and Pardo J. Mouse cytotoxic T cell-derived granzyme B activates the mitochondrial cell death pathway in a Bim-dependent fashion. The Journal of biological chemistry. 2015; 290(11):6868-6877.
45. Horikawa M, Minard-Colin V, Matsushita T and Tedder TF. Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. The Journal of clinical investigation. 2011; 121(11):4268-4280.
46. Zhou J, Min Z, Zhang D, Wang W, Marincola F and Wang X. Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer. Journal of translational medicine. 2014; 12:304.
47. Shao Y, Lo CM, Ling CC, Liu XB, Ng KT, Chu AC, Ma YY, Li CX, Fan ST and Man K. Regulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway. Cancer letters. 2014; 355(2):264-272.
48. Kaltenmeier C, Gawanbacht A, Beyer T, Lindner S, Trzaska T, van der Merwe JA, Harter G, Gruner B, Fabricius D, LotfiR, Schwarz K, Schutz C, Honig M, et al. CD4+ T cellderived IL-21 and deprivation of CD40 signaling favor the in vivo development of granzyme B-expressing regulatory B cells in HIV patients. Journal of immunology. 2015; 194(8):3768-3777.
49. Lin W, Jin L, Chen H, Wu Q, Fei Y, Zheng W, Wang Q, Li P, Li Y, Zhang W, Zhao Y, Zeng X and Zhang F. B cell subsets and dysfunction of regulatory B cells in IgG4-related diseases and primary Sjogren's syndrome: the similarities and differences. Arthritis research & therapy. 2014; 16(3):R118.
50. Berthelot JM, Jamin C, Amrouche K, Le GoffB, Maugars Y and Youinou P. Regulatory B cells play a key role in immune system balance. Joint, bone, spine: revue du rhumatisme. 2013; 80(1):18-22.
51. Rosser EC, Oleinika K, Tonon S, Doyle R, Bosma A, Carter NA, Harris KA, Jones SA, Klein N and Mauri C. Regulatory B cells are induced by gut microbiota-driven interleukin-1beta and interleukin-6 production. Nature medicine. 2014; 20(11):1334-1339.
52. Vadasz Z, Haj T, Kessel A and Toubi E. B-regulatory cells in autoimmunity and immune mediated inflammation. FEBS letters. 2013; 587(13):2074-2078.
53. Wang RX, Yu CR, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, Wingfield PT, Kim SH and Egwuagu CE. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nature medicine. 2014; 20(6):633-641.
54. Han S, Feng S, Ren M, Ma E, Wang X, Xu L and Xu M. Glioma cell-derived placental growth factor induces regulatory B cells. The international journal of biochemistry & cell biology. 2014; 57:63-68.
55. Li Y, An J, Huang S, He J and Zhang J. Esophageal cancerderived microvesicles induce regulatory B cells. Cell biochemistry and function. 2015; 33(5):308-313.
56. Tedder TF. B10 cells: a functionally defined regulatory B cell subset. Journal of immunology. 2015; 194(4):1395-1401.
57. Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, et al. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014; 124(13):2034-2045.
58. DiLillo DJ, Weinberg JB, Yoshizaki A, Horikawa M, Bryant JM, Iwata Y, Matsushita T, Matta KM, Chen Y, Venturi GM, Russo G, Gockerman JP, Moore JO, et al. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia. 2013; 27(1):170-182.
59. Chen T, Song D, Min Z, Wang X, Gu Y, Wei B, Yao J, Chen K, Jiang Z, Xie H, Zhou L and Zheng S. Perioperative dynamic alterations in peripheral regulatory T and B cells in patients with hepatocellular carcinoma. Journal of translational medicine. 2012; 10:14.
60. Liu J, Wang H, Yu Q, Zheng S, Jiang Y, Liu Y, Yuan G and Qiu L. Aberrant frequency of IL-10-producing B cells and its association with Treg and MDSC cells in non small cell lung carcinoma patients. Human immunology. 2016; 77(1):84-89.
61. Wei X, Jin Y, Tian Y, Zhang H, Wu J, Lu W and Lu X. Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients. Tumour biology. 2016; 37(5):6581-6588.
62. Zhou X, Su YX, Lao XM, Liang YJ and Liao GQ. CD19(+) IL-10(+) regulatory B cells affect survival of tongue squamous cell carcinoma patients and induce resting CD4(+) T cells to CD4(+)Foxp3(+) regulatory T cells. Oral oncology. 2016; 53:27-35.
63. Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, Ries S, Dang VD, Jaimes Y, Daridon C, Li R, Jouneau L, Boudinot P, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014; 507(7492):366-370.
64. Tedder TF and Leonard WJ. Autoimmunity: regulatory B cells-IL-35 and IL-21 regulate the regulators. Nature reviews rheumatology. 2014; 10(8):452-453.
65. Zhang Y, Sun H, Wu H, Tan Q and Xiang K. Interleukin 35 is an independent prognostic factor and a therapeutic target for nasopharyngeal carcinoma. Contemporary oncology. 2015; 19(2):120-124.
66. Fan YG, Zhai JM, Wang W, Feng B, Yao GL, An YH and Zeng C. IL-35 over-expression is associated with genesis of gastric cancer. Asian Pacific journal of cancer prevention. 2015; 16(7):2845-2849.
67. Pylayeva-Gupta Y, Das S, Handler JS, Hajdu CH, Coffre M, Koralov SB and Bar-Sagi D. IL35-producing B cells promote the development of pancreatic neoplasia. Cancer discovery. 2016; 6(3):247-255.
68. Ye ZP, He HY, Wang H, Li WS, Luo L, Huang ZC and Guo Y. Glioma-derived ADAM10 induces regulatory B cells to suppress CD8+ T cells. PloS one. 2014; 9(8):e105350.
69. Jensen-Jarolim E, Fazekas J, Singer J, Hofstetter G, Oida K, Matsuda H and Tanaka A. Crosstalk of carcinoembryonic antigen and transforming growth factor-beta via their receptors: comparing human and canine cancer. Cancer immunology, immunotherapy. 2015; 64(5):531-537.
70. Saitoh M, Endo K, Furuya S, Minami M, Fukasawa A, Imamura T and Miyazawa K. STAT3 integrates cooperative Ras and TGF-beta signals that induce Snail expression. Oncogene. 2016; 35(8):1049-1057.
71. Peng X, Luo Z, Kang Q, Deng D, Wang Q, Peng H, Wang S and Wei Z. FOXQ1 mediates the crosstalk between TGF-beta and Wnt signaling pathways in the progression of colorectal cancer. Cancer biology & therapy. 2015; 16(7):1099-1109.
72. Kessel A, Haj T, Peri R, Snir A, Melamed D, Sabo E and Toubi E. Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmunity reviews. 2012; 11(9):670-677.
73. Nouel A, Pochard P, Simon Q, Segalen I, Le Meur Y, Pers JO and Hillion S. B-Cells induce regulatory T cells through TGF-beta/IDO production in a CTLA-4 dependent manner. Journal of autoimmunity. 2015; 59:53-60.
74. Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM and Balkwill FR. B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(26):10662-10667.
75. Tretter T, Venigalla RK, Eckstein V, Saffrich R, Sertel S, Ho AD and Lorenz HM. Induction of CD4+ T-cell anergy and apoptosis by activated human B cells. Blood. 2008; 112(12):4555-4564.
76. Rosser EC and Mauri C. Regulatory B cells: origin, phenotype, and function. Immunity. 2015; 42(4):607-612.
77. Biswas SK and Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature immunology. 2010; 11(10):889-896.
78. Bodogai M, Moritoh K, Lee-Chang C, Hollander CM, Sherman-Baust CA, Wersto RP, Araki Y, Miyoshi I, Yang L, Trinchieri G and Biragyn A. Immunosuppressive and prometastatic functions of myeloid-derived suppressive cells rely upon education from tumor-associated B cells. Cancer research. 2015; 75(17):3456-3465.
79. Xing C, Ma N, Xiao H, Wang X, Zheng M, Han G, Chen G, Hou C, Shen B, Li Y and Wang R. Critical role for thymic CD19+CD5+CD1dhiIL-10+ regulatory B cells in immune homeostasis. Journal of leukocyte biology. 2015; 97(3):547-556.
80. Wang Z, Cheng Q, Tang K, Sun Y, Zhang K, Zhang Y, Luo S, Zhang H, Ye D and Huang B. Lipid mediator lipoxin A4 inhibits tumor growth by targeting IL-10-producing regulatory B (Breg) cells. Cancer letters. 2015; 364(2):118-124.
81. Zheng M, Xing C, Xiao H, Ma N, Wang X, Han G, Chen G, Hou C, Shen B, Li Y and Wang R. Interaction of CD5 and CD72 is involved in regulatory T and B cell homeostasis. Immunological investigations. 2014; 43(7):705-716.
82. Biragyn A, Lee-Chang C and Bodogai M. Generation and identification of tumor-evoked regulatory B cells. Methods in molecular biology. 2014; 1190:271-289.
83. Zhang Y, Morgan R, Podack ER and Rosenblatt J. B cell regulation of anti-tumor immune response. Immunologic research. 2013; 57(1-3):115-124.
84. Zhang Y, Morgan R, Chen C, Cai Y, Clark E, Khan WN, Shin SU, Cho HM, Al Bayati A, Pimentel A and Rosenblatt JD. Mammary-tumor-educated B cells acquire LAP/TGF-beta and PD-L1 expression and suppress anti-tumor immune responses. International immunology. 2016.
85. Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, Jamieson C, Kane CJ, Klatte T, et al. Immunosuppressive plasma cells impede T-celldependent immunogenic chemotherapy. Nature. 2015; 521(7550):94-98.
86. Schietinger A and Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends in immunology. 2014; 35(2):51-60.
87. Tang A, Dadaglio G, Oberkampf M, Di Carlo S, Peduto L, Laubreton D, Desrues B, Sun CM, Montagutelli X and Leclerc C. B cells promote tumor progression in a mouse model of HPV-mediated cervical cancer. International journal of cancer Journal international du cancer. 2016.
88. Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, SteinhoffM, Li Y, Gong Q, Ma Y, Wiesen JF, Wong MH, et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer cell. 2014; 25(6):809-821.
89. Hojyo S, Sarkander J, Manne C, Mursell M, Hanazawa A, Zimmel D, Zhu J, Paul WE, Fillatreau S, Lohning M, Radbruch A and Tokoyoda K. B cells negatively regulate the establishment of CD49b(+)T-bet(+) resting memory T helper cells in the bone marrow. Frontiers in immunology. 2016; 7:26.
90. Novinger LJ, Ashikaga T and Krag DN. Identification of tumor-binding scFv derived from clonally related B cells in tumor and lymph node of a patient with breast cancer. Cancer immunology, immunotherapy. 2015; 64(1):29-39.
91. Woo JR, Liss MA, Muldong MT, Palazzi K, Strasner A, Ammirante M, Varki N, Shabaik A, Howell S, Kane CJ, Karin M and Jamieson CA. Tumor infiltrating B-cells are increased in prostate cancer tissue. Journal of translational medicine. 2014; 12:30.
92. Vivanco BC, Viana JD, Perez EC, Konno FT, Guereschi MG, Xander P, Keller AC and Lopes JD. B-1 cells promote immunosurveillance against murine melanoma in host absence of CCR5: new perspective in autologous vaccination therapy. Immunobiology. 2014; 219(11):845-849.
93. Ammirante M, Luo JL, Grivennikov S, Nedospasov S and Karin M. B-cell-derived lymphotoxin promotes castrationresistant prostate cancer. Nature. 2010; 464(7286):302-305.
94. Ammirante M, Kuraishy AI, Shalapour S, Strasner A, Ramirez-Sanchez C, Zhang W, Shabaik A and Karin M. An IKKalpha-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes & development. 2013; 27(13):1435-1440.
95. Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, Korets L, Lam J, Tawfik D, DeNardo DG, Naldini L, de Visser KE, De Palma M, et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer cell. 2010; 17(2):121-134.
96. de Visser KE, Korets LV and Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer cell. 2005; 7(5):411-423.
97. Liu Y, Liu D, Wang C, Liao Q, Huang J, Jiang D, Shao W, Yin CC, Zhang Y, Lee G and Qiu X. Binding of the monoclonal antibody RP215 to immunoglobulin G in metastatic lung adenocarcinomas is correlated with poor prognosis. Histopathology. 2015; 67(5):645-653.